Manufacturer of Controlled Substances; Notice of Registration; GE Healthcare, 14300 [2014-05484]

Download as PDF 14300 Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices Drug Schedule Noroxymorphone (9668) .............. Poppy Straw Concentrate (9670) Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ II II II II II II The company plans to manufacture the listed controlled substances in bulk for sale to its customers, for dosage form development, for clinical trials, and for use in stability qualification studies. No comments or objections have been received. The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambrex Charles City, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. The DEA has investigated Cambrex Charles City, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: February 19, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. BILLING CODE 4410–09–P DEPARTMENT OF LABOR Occupational Safety and Health Administration [Docket Number: OSHA–2014–0004] Occupational Safety and Health Administration (OSHA), DOL. ACTION: Request for nominations to serve on the Whistleblower Protection Advisory Committee. DEPARTMENT OF JUSTICE The Assistant Secretary of Labor for Occupational Safety and Health requests nominations for membership on the Whistleblower Protection Advisory Committee (WPAC). SUMMARY: Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; GE Healthcare TKELLEY on DSK3SPTVN1PROD with NOTICES [FR Doc. 2014–05484 Filed 3–12–14; 8:45 am] AGENCY: BILLING CODE 4410–09–P By Notice dated October 16, 2013, and published in the Federal Register on October 25, 2013, 78 FR 64018, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004–1412, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II. The company plans to manufacture a radioactive product to diagnose Parkinson’s disease for distribution to its customers. 17:33 Mar 12, 2014 Dated: February 19, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Whistleblower Protection Advisory Committee [FR Doc. 2014–05495 Filed 3–12–14; 8:45 am] VerDate Mar<15>2010 No comments or objections have been received. The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of GE Healthcare to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. The DEA has investigated GE Healthcare to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Jkt 232001 Nominations for WPAC must be submitted (postmarked, sent, transmitted, or received) by May 12, 2014. DATES: You may submit nominations for WPAC, identified by the OSHA Docket No., OSHA–2014– 0004, by any of the following methods: Electronically: Nominations, including attachments, may be submitted electronically at https:// www.regulations.gov, which is the Federal eRulemaking Portal. Follow the instructions online for making electronic submissions. ADDRESSES: PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 Facsimile: If your nomination and supporting materials, including attachments, do not exceed 10 pages, you may fax them to the OSHA Docket Office at (202) 693–1648. Mail, hand delivery, express mail, messenger or courier service: Submit your nominations and supporting materials to the OSHA Docket Office, Docket No. OSHA–2014–0004, U.S. Department of Labor, Room N–2625, 200 Constitution Avenue NW., Washington, DC 20210; telephone (202) 693–2350 (OSHA’s TTY number is (877) 889–5627). Deliveries (hand, express mail, messenger and courier service) are accepted during the Department of Labor’s and Docket Office’s normal business hours, 8:15 a.m.–4:45 p.m., e.t. Instructions: All nominations and supporting materials for WPAC must include the Agency name and docket number for this Federal Register notice (Docket No. OSHA–2014–0004). Because of security-related procedures, submitting nominations by regular mail may result in a significant delay in their receipt. Please contact the OSHA Docket Office for information about security procedures for submitting nominations by hand delivery, express delivery, and messenger or courier service. For additional information on submitting nominations see the ‘‘Public Participation—Submission of Nominations and Access to Docket’’ heading in the SUPPLEMENTARY INFORMATION section below. Submissions in response to this Federal Register notice, including personal information provided, are posted without change at https:// www.regulations.gov. Therefore, OSHA cautions interested parties about submitting personal information such as social security numbers and dates of birth. Docket: To read or download submissions or other material in the docket, go to https://www.regulations.gov or the OSHA Docket Office at the address above. All documents in the docket are listed in the https:// www.regulations.gov index; however, some information (e.g., copyrighted material) is not publicly available to read or download through that Web site. All submissions, including copyrighted material, are available for inspection and copying at the OSHA Docket Office. FOR FURTHER INFORMATION CONTACT: Meghan Smith, OSHA, Directorate of Whistleblower Protection Programs, U.S. Department of Labor, Room N– 4624, 200 Constitution Avenue NW., Washington, DC 20210; telephone (202) 693–2199; email address smith.meghan.p@dol.gov. E:\FR\FM\13MRN1.SGM 13MRN1

Agencies

[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Page 14300]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05484]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; GE 
Healthcare

    By Notice dated October 16, 2013, and published in the Federal 
Register on October 25, 2013, 78 FR 64018, GE Healthcare, 3350 North 
Ridge Avenue, Arlington Heights, Illinois 60004-1412, made application 
by renewal to the Drug Enforcement Administration (DEA) to be 
registered as a bulk manufacturer of Cocaine (9041), a basic class of 
controlled substance listed in schedule II.
    The company plans to manufacture a radioactive product to diagnose 
Parkinson's disease for distribution to its customers.
    No comments or objections have been received. The DEA has 
considered the factors in 21 U.S.C. 823(a) and determined that the 
registration of GE Healthcare to manufacture the listed basic class of 
controlled substance is consistent with the public interest at this 
time. The DEA has investigated GE Healthcare to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 
1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic class of controlled substance listed.

    Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2014-05484 Filed 3-12-14; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.